

LUC
0
10
20
30
40
0
0.1
0.2
0.5
1
2
5
Butyrate (mM)
LUC
0
10
20
30
0
0.01
0.1
0.2
0.5
1
2
4
5' - Azad (uM)
LUC
0
10
20
30
0
0.1
0.2
0.5
1
2
5
Valproate (mM)
LUC
0
10
20
30
0
0.1
0.2
0.5
1
2
5
Valproate (mM)

FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C



RFU
30000
25000
20000
15000
10000
5000
0
0
100
300
500
1000
Azad(nM)

FIG. 3




FIG. 4

BX-1

RPMI

day0	1	2	3	4	5	6	7	8	9	10	11	12
A	18011	18375	19733	19990	20480	19980	20531	20596	19786	19784	19272	16272
B	18423	19526	20272	19941	20865	20698	21314	20759	21156	19806	19498	16368
C	16224	17039	18445	16899	16964	18170	17125	17096	16675	16206	15971	16811
D	17555	18058	18318	20145	19870	19919	19529	21625	19545	20014	18146	16455
E	20758	20136	19951	19839	20929	20253	19793	20059	19721	16907	16272	16643
F	19332	19023	20613	20016	19008	19743	18969	19382	17443	18730	17878	16169
G	16232	15988	15959	16338	16682	17031	17248	17954	18050	20037	19397	16297
H	16711	17728	16065	16786	16298	18953	19295	19460	20072	19185	18560	15837
	3											

+anti-IgG

FIG. 4A

day3	1	2	3	4	5	6	7	8	9	10	11	12
A	28206	25054			40322	27800	30039	23158	29578	29313	30764	15790
B	28899	29276	34041		34503	28346	30093	33855	30640	26455	35615	16356
C	29453	23635	36968	24244	28804	26418	23579	23313	20921	20206	21088	16545
D	25854	25604	26258	25818	20248	26940	26342	29047	27235	34097	25038	16472
E	56465	26496	27788	26429	28103	30624	27840	28430	25572	21853	20670	16113
F	53591	28886	32731	27978	29681	28896	27183	28810	23983		30424	16058
G	36820	22421	21136	22620	23215	23330	24427	36006	27262	31690	27473	15724
H	46840	23551	28892	30887	23590	25038	26919	28925		30030	28702	15718
3												

Doxorubicin

day17	1	2	3	4	5	6	7	8	9	10	11	12
A	24748	18470	22917	29402	29988	15010	18326	7058	25386	17975	23082	5069
B	21980	20655	28523	29514	19339	20420	20740	16821	18195	16169	23830	5215
C	22496	18290	33159	16745	23229	21244	23257	21433	22182	22235	22708	5306
D	21576	19676	19190	16909			20204	19787	20972	23296	20569	5320
E	16591	16073	18721	15424	20062	20602		20122	17275	21432	22609	5176
F	16403	19815			20229	21643	21895	20467	22109	40151	32366	5100
G	17632	20734	20291	21025	20609	22434	21019	26082	22597	23390		5152
H	18059	18172	24413	26990	22705	20611	21584	23046	16745	22222	21182	4541
1												

FIG. 4B



GFP
Most glucocorticoid drugs
Anti-IgG,
PMA
Some glucocorticoid drugs
Doxorubicin
Gemcitabin
Luciferase
Methotrexate,
cis-platinum,
5-FU,
Taxol

FIG. 5





FIG. 6A
FIG. 6B

FIG. 6


25.0
20.0
15.0
10.0
5.0
0.0
Inc
0
0.1
1
5
10
50
100
300
500
1000
tranilast(uM)
O
N
H
O
O
H
O
O
Tranilast

FIG. 6A






Leflunomide

Tranilast and Lefunomide can induce BZLF1 promoter in AGS up to 15 fold

FIG. 6B



Ara-c

FIG. 7A



Inc fold induction
2.5
2
1.5
1
0.5
0
0
0.1
0.2
0.5
1
2
5
10
20
50
100
200
Ara-c (uM)

FIG. 7B




FIG. 7C




FIG. 8A




FIG. 8B





FIG. 8C







FIG. 8D



Indoprofen

FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B





FIG. 10C



Mebendazol

FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D



FIG. 11E

FIG. 12A





FIG. 12B






FIG. 12C




FIG. 12D




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D






FIG. 14A

FIG. 14B




72 hr

FIG. 15A




96 hr

FIG. 15B



3 hr


FIG. 16A



TK143b


24 hr

FIG. 16B



3 hr

FIG. 16C



V143b (+ bortezomib)

24 hr

FIG. 16D



Tumor
Liver
Kidney
Spleen
Muscle
%ID/gram
0
2
4
6
2
14
24
48
72
96
Hours

FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B




FIG. 19C

FIG. 20B





FIG. 20A





Day 0
Day 5
Day 10
Day 15
no treatment
GCV + [131I]FIAU
Velcade + [131I]FIAU

FIG. 21



1400
1200
1000
800
600
400
200
0
Tumor volume (mm3)
Day 0 Day 2 Day 5 Day 8Day 12Day 15
Days after treatment
no treatment
[131I]FIAU + GCV
[131I]FIAU + bortezomib

FIG. 22



Bystander effect
TK expressing cell
[131I]FIAU

FIG. 23




FIG. 24



Cell Dose
<AD> = 4.36 Gy
Cells
Dose (Gy)
131 Dose Distribution vs. Cell Position
Dose (Gy)
Radius (mm)
Cell Dose
<AD> = 4.35 Gy
Cells
Dose (Gy)
131 Dose Distribution vs. Cell Position
Dose (Gy)
Radius (mm)
Cell Dose
<AD> = 4.34 Gy
Cells
Dose (Gy)
131 Dose Distribution vs. Cell Position
Dose (Gy)
Radius (mm)

FIG. 25




FIG. 26




FIG. 26A




FIG. 26B




FIG. 26C